TY - JOUR AU - Heeley E. AU - Stapf C. AU - Robinson T. AU - Wang J. AU - Wang X. AU - Arima H. AU - Delcourt C. AU - Sato S. AU - Anderson Craig AU - Lavados P. AU - Chan E. AU - Saxena A. AU - Munoz-Venturelli P. AU - Chalmers J. AU - Neal Bruce AB -

BACKGROUND AND PURPOSE: We aimed to determine associations of baseline blood glucose and diabetes mellitus with clinical outcomes in participants of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). METHODS: INTERACT2 was an international prospective, open, blinded end point, randomized controlled trial of 2839 patients with spontaneous intracerebral hemorrhage (<6 hours) and elevated systolic blood pressure randomly assigned to intensive (target systolic blood pressure <140 mm Hg) or guideline-based (systolic blood pressure <180 mm Hg) BP management. Associations of hyperglycemia at presentation (>6.5 mmol/L) and combined and separate poor outcomes of death and major disability (scores of 3-6, 3-5, and 6, respectively, on the modified Rankin scale) at 90 days were determined in logistic regression models. RESULTS: In 2653 patients with available data, there were 1348 (61%) with hyperglycemia and 292 (11%) with diabetes mellitus. Associations of baseline blood glucose and poor outcome were strong and near continuous. After adjustment for baseline variables, the highest fourth (7.9-25.0 mmol/L) of blood glucose was significantly associated with combined poor outcome (adjusted odds ratio 1.35, 95% confidence interval 1.01-1.80; P trend 0.015). Diabetes mellitus also predicted poor outcome (adjusted odds ratio 1.46, 95% confidence interval 1.05-2.02; P=0.023), though more important for residual disability than death on separate analysis. CONCLUSIONS: Hyperglycemia and diabetes mellitus are independent predictors of poor outcome in patients with predominantly mild to moderate severity of intracerebral hemorrhage. These data support guideline recommendations for good glycemic control in patients with intracerebral hemorrhage. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.

AD - From the The George Institute for Global Health, Royal Prince Alfred Hospital, Sydney, NSW, Australia (A.S., C.S.A., X.W., S.S., H.A., E.C., P.M.-V., C.D., B.N., J.C., E.H.); Central Clinical School, University of Sydney, Sydney, Australia (A.S., C.S.A., X.W., E.C., P.M.-V., C.D., B.N., J.C., E.H.); Center for Epidemiologic Research in Asia, Shiga University of Medical Science, Japan (H.A.); Clinica Alemana de Santiago, Universidad del Desarrollo, Chile (P.M.-V., P.M.L.); Department of Cardiovascular Sciences and NIHR Biomedical Research Unit in Cardiovascular Disease, University of Leicester, Leicester, UK (T.R.); CRCHUM, Departement de Neurosciences, Universite de Montreal, Montreal, QC, Canada (C.S.); Departamento de Ciencias Neurologicas, Facultad de Medicina, Universidad de Chile (P.M.L.); and The Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China (J.W.).
From the The George Institute for Global Health, Royal Prince Alfred Hospital, Sydney, NSW, Australia (A.S., C.S.A., X.W., S.S., H.A., E.C., P.M.-V., C.D., B.N., J.C., E.H.); Central Clinical School, University of Sydney, Sydney, Australia (A.S., C.S.A., X.W., E.C., P.M.-V., C.D., B.N., J.C., E.H.); Center for Epidemiologic Research in Asia, Shiga University of Medical Science, Japan (H.A.); Clinica Alemana de Santiago, Universidad del Desarrollo, Chile (P.M.-V., P.M.L.); Department of Cardiovascular Sciences and NIHR Biomedical Research Unit in Cardiovascular Disease, University of Leicester, Leicester, UK (T.R.); CRCHUM, Departement de Neurosciences, Universite de Montreal, Montreal, QC, Canada (C.S.); Departamento de Ciencias Neurologicas, Facultad de Medicina, Universidad de Chile (P.M.L.); and The Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China (J.W.). canderson@george.org.au. AN - 26814235 BT - Stroke DA - 93657095517 DP - NLM ET - 2016/01/28 LA - Eng LB - AUS
PDO
NMH
FY16 N1 - Saxena, Anubhav
Anderson, Craig S
Wang, Xia
Sato, Shoichiro
Arima, Hisatomi
Chan, Edward
Munoz-Venturelli, Paula
Delcourt, Candice
Robinson, Thompson
Stapf, Christian
Lavados, Pablo M
Wang, Jiguang
Neal, Bruce
Chalmers, John
Heeley, Emma
Stroke. 2016 Jan 26. pii: STROKEAHA.115.011627. N2 -

BACKGROUND AND PURPOSE: We aimed to determine associations of baseline blood glucose and diabetes mellitus with clinical outcomes in participants of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). METHODS: INTERACT2 was an international prospective, open, blinded end point, randomized controlled trial of 2839 patients with spontaneous intracerebral hemorrhage (<6 hours) and elevated systolic blood pressure randomly assigned to intensive (target systolic blood pressure <140 mm Hg) or guideline-based (systolic blood pressure <180 mm Hg) BP management. Associations of hyperglycemia at presentation (>6.5 mmol/L) and combined and separate poor outcomes of death and major disability (scores of 3-6, 3-5, and 6, respectively, on the modified Rankin scale) at 90 days were determined in logistic regression models. RESULTS: In 2653 patients with available data, there were 1348 (61%) with hyperglycemia and 292 (11%) with diabetes mellitus. Associations of baseline blood glucose and poor outcome were strong and near continuous. After adjustment for baseline variables, the highest fourth (7.9-25.0 mmol/L) of blood glucose was significantly associated with combined poor outcome (adjusted odds ratio 1.35, 95% confidence interval 1.01-1.80; P trend 0.015). Diabetes mellitus also predicted poor outcome (adjusted odds ratio 1.46, 95% confidence interval 1.05-2.02; P=0.023), though more important for residual disability than death on separate analysis. CONCLUSIONS: Hyperglycemia and diabetes mellitus are independent predictors of poor outcome in patients with predominantly mild to moderate severity of intracerebral hemorrhage. These data support guideline recommendations for good glycemic control in patients with intracerebral hemorrhage. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.

PY - 2016 SN - 1524-4628 (Electronic)
0039-2499 (Linking) SP - 682 EP - 8 T2 - Stroke TI - Prognostic Significance of Hyperglycemia in Acute Intracerebral Hemorrhage: The INTERACT2 Study VL - 47 Y2 - FY16 ER -